PABA (Para-Aminobenzoic Acid)

Clinical Summary

PABA is a naturally occurring aromatic amino acid and a precursor to folic acid — but only in bacteria and plants, not in humans. We lack the enzyme (dihydropteroate synthase) needed to incorporate PABA into folate. The "Vitamin B10" designation is a historical misnomer that persists in marketing.

PABA has three distinct identities:

1. OTC supplement (100-500mg) — marketed primarily for gray hair prevention and oral sun protection. Evidence for both uses is weak: historical observational reports from the 1940s-50s, never replicated in controlled trials.
2. Prescription drug (Potaba/KPAB) (12g/day) — used for Peyronie's disease, scleroderma, and dermatomyositis. Two RCTs exist: Weidner 2005 (Peyronie's, N=103) showed plaque stabilization but NO curvature improvement; Clegg 1994 (scleroderma, N=146) was NULL across all endpoints. FDA NDA 007663 withdrawn 9 March 2022 for insufficient efficacy evidence (Federal Register Vol. 87, No. 46). EAU 2025 and AUA 2015 guidelines both recommend AGAINST oral PABA for Peyronie's. Cochrane 2023 and Lee 2024 NMA did not endorse it.
3. Topical sunscreen — first-generation UVB filter (1940s-1990s), now phased out due to photoallergic contact dermatitis and clothing staining. Replaced by PABA esters (Padimate O). JAAD 2025 sunscreen review (PMID 38777185) confirms off-market status.

A fourth emerging identity is bacterial infection imaging tracer — 11C-PABA and 18F-PABA PET exploit the fact that bacteria (but not mammals) synthesize folate de novo from PABA. NCT05611905 completed first-in-human biodistribution in November 2025 (PMID 40153540). This is a diagnostic, not supplement, application.

PABA is also of interest as a metabolite of procaine (Novocaine) — the basis of the Romanian anti-aging drug Gerovital H3 (Ana Aslan, 1950s). PABA + DMAE are procaine's two hydrolysis products.

Nearly the entire historical therapeutic evidence base traces to one researcher: Constantine J. Zarafonetis (University of Michigan, 1940s-1980s). His work on anti-fibrotic uses, hair repigmentation, and rickettsial disease treatment was never independently confirmed at scale — and where modern RCTs were attempted (Clegg 1994 scleroderma), they were NULL. This is the central weakness of the PABA evidence base.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend: 5/5=multiple large RCTs+MA | 4/5=several human RCTs | 3/5=some human pilot data | 2/5=animal/very limited human | 1/5=none/debunked

Peyronie's Disease — Weidner 2005, Now Superseded

Weidner 2005 (PMID 15774254) remains the only placebo-controlled RCT for Peyronie's — multicenter, double-blind, N=103 (75 completers), 12g/day Potaba × 12 months. Result: 74.3% response vs 50% placebo (p=0.016) for plaque stabilization. No significant improvement in curvature (p=0.066), pain, or sexual function vs placebo. Park 2016 (Korea, PMID 27169128) found Potaba monotherapy inferior to combination therapy with high dropout due to GI side effects.

Modern synthesis rejects the signal:

• AUA 2015 (PMID 26066402): "Clinicians should not offer potassium para-aminobenzoate for the reduction of penile curvature" (Moderate Recommendation).
• EAU 2025 (PMID 40340108): Strong recommendation AGAINST oral treatment for curvature correction.
• Cochrane 2023 (PMID 37490423, 14 RCTs, 1,810 men): PABA not among interventions with supporting evidence; only injectional collagenase had moderate-certainty for modest curvature change.
• Lee 2024 NMA (PMID 37382281, 24 RCTs, 1,643 patients): PABA NOT among the 7 monotherapies or 2 combinations with statistically significant benefit; SUCRA ranked it low.
• Tienforti 2024 (PMID 38807529, Sex Med Rev): Nutraceutical review — PABA remains the only PD nutraceutical with a historical signal, but evidence is old, dropout heavy, pill burden impractical.
• French AFU 2021 (PMID 33941460): Oral PABA not recommended.

Scleroderma — The NULL RCT

Clegg 1994 (PMID 8151563) is the pivotal modern scleroderma RCT: N=146, 48 weeks, KPAB 12g/day vs placebo. NULL across all endpoints — no benefit on skin mobility, thickening, oral aperture, or hand range of motion. 18 KPAB vs 6 placebo withdrew for adverse events (GI intolerance, headaches). This trial was the explicit basis for the FDA efficacy rejection in scleroderma. Zarafonetis's 1988 retrospective (PMID 3180546, N=467, 90% skin softening) — repeatedly cited in older Potaba literature — was not reproduced by the controlled trial. Modern ACR scleroderma treatment algorithms do not include PABA; the community (Inspire Scleroderma Foundation forums) has abandoned it in favor of mycophenolate and biologics.

Hair Repigmentation — Historical Only

Sieve (1941, published in Science) administered 200mg/day to ~460 subjects and reported 82% favorable response. Zarafonetis (1950, PMID 14794992) observed gray hair darkening in patients on PABA for other conditions. A later study combining 200mg PABA + 100mg calcium pantothenate found only 6% definite color change after 8 months. The 2020 systematic review on premature graying (PMID 32654282) classifies PABA as "low-grade recommendation (2A)" — historical mention, not endorsement. Effect is reportedly REVERSIBLE — hair returns to gray within 2-4 weeks of discontinuation per community reports. No modern RCT exists.

Prescribing

Dosing Table

Formulation Table

Safety

Interactions Table

Contraindications

• Active sulfonamide antibiotic therapy (absolute)
• Known PABA hypersensitivity or para-amino group allergy (cross-reactivity with sulfonamides, azo dyes, PPD hair dyes, benzocaine/procaine)
• Severe hepatic impairment (at any dose above supplement level)
• Renal insufficiency at therapeutic doses (12g/day produces significant metabolite load)

Adverse Effects (ranked by frequency)

At supplement doses (≤500mg/day): Generally well-tolerated. Occasional mild GI upset (nausea).

At high doses (>2g/day) and Potaba doses (12g/day):

1. GI intolerance — nausea, anorexia, vomiting (very common; Clegg 1994 had 18/73 KPAB withdrawals vs 6/73 placebo; Park 2016 68.2% dropout; peyroniesforum.net users routinely drop dose to 6-8g just to tolerate).
2. Hepatotoxicity (DILI) — 8-10 published case reports of acute liver injury at Potaba doses (12g/day), plus one autoimmune-hepatitis case from a PABA-containing hair supplement (ACG 2020 case report — 37F). All resolved on discontinuation. Most recent detailed case: Plüss 2022 (PMID 36059975) — RUCAM "highly probable," T-cell mediated (HLA-DR+). FAERS corroborates: DILI is the dominant serious reaction (4 reports out of ~37 Potaba FAERS entries — disproportionate for the small exposure pool). Zarafonetis 1986 (PMID 3487559) reviewed 390 scleroderma patients and found NO hepatic hypersensitivity from Potaba — LFT elevations were actually more frequent in the untreated group. Pharma skepticism note: ~10 cases across 60+ years of use in thousands of patients suggests LOW absolute risk, but the mechanism (immune-mediated) is unpredictable, and the FAERS signal is real.
3. Hypoglycemia — reported at high oral doses (PMID 6608591). Mechanism unclear.
4. DRESS syndrome — 1 case report (PMID 39292842, 2024). Confirmed by positive patch test. Serious but extremely rare.
5. Skin rash / allergic reaction — moderate frequency in community reports and FAERS (erythema + macular rash are top-count suspect reactions); especially in individuals sensitive to para-amino compounds.
6. Systemic photosensitization — paradoxical: 1 case report of photosensitization FROM oral PABA (PMID 20153994), contradicting the folk "oral sunscreen" claim.
7. Contact dermatitis from topical PABA sunscreens — well-established historical AE (PMID 39640469 2024 Indian Dermatol Online J; PMID 38777185 2025 JAAD). Reason PABA sunscreens were phased out in US/EU.

FAERS Signal Table (from BioMCP)

Reading FAERS data: Combined Potaba brand (37 reports) + aminobenzoate potassium generic (7 reports) ≈ 44 unique FAERS entries. Of these, only ~10 have PABA as suspect drug — the rest list other drugs as suspect with PABA as concomitant. The "para-aminobenzoic acid" free-text search is contaminated by procaine/benzocaine metabolite reports and unreliable. DILI is the dominant suspect-drug signal (4 reports of 37), disproportionate relative to the low total volume. The FAERS signal corroborates the published case series, not the reverse.

Monitoring Table

Thyroid Safety Signal

Hasumura 2005 (PMID 15843508, Japanese study): PABA promoted thyroid carcinogenesis in DHPN-initiated rats. This is a chemical carcinogenesis model (DHPN initiator + PABA promoter), not spontaneous cancer. Relevance to humans at supplement doses is unclear but warrants noting. No human thyroid cancer signal exists in FAERS or epidemiological data. Periodic thyroid monitoring (TSH, FT3, FT4) is prudent for long-term high-dose users, particularly those also taking iodine-containing supplements.

Synergies & Stacking

Stack conflict notes:

• If you already supplement methylfolate directly (e.g., L-5-MTHF), PABA's folate-precursor role is biologically redundant in humans (we lack DHPS). Any gut-microbial folate contribution remains theoretical.
• Redundant when a complete B-complex is already being taken.
• No meaningful conflicts with other common supplements at doses ≤500mg/day.
• Absolute conflict: any sulfonamide antibiotic course. Stop PABA for the duration.

Individual Response Modifiers

Only modifiers with evidence for PABA specifically are listed. If a factor has no compound-specific evidence, it is omitted — this is not a general genetics textbook.

Sex-Specific Considerations

Genetic Modifiers

Evidence basis: Almost all pharmacogenomic data on PABA is as a probe drug for acetylation phenotyping, not as an intervention. No large clinical study has stratified PABA outcomes by genotype. The HLA-linked DILI observation is a single case. Be skeptical of marketing that claims "PABA genotype testing" predicts response.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed across ~200-400 visible reports (iHerb, WebMD, Longecity, peyroniesforum.net, Inspire Scleroderma Foundation, JP/KR forums). PABA is a "forgotten B vitamin" with a small but persistent following concentrated on gray-hair prevention and Peyronie's disease. Enthusiasm tempered by awareness of limited clinical data; scleroderma community has largely abandoned it.

What Users Report

Notable long-term anecdotes: WebMD user started PABA at 35 (up to 700mg/day), reports "no gray hair at age 68." Another started at 44 in 1983, reports "only about 1/3 gray" at 73. One Inspire scleroderma user: "26 pills/day for years in the 1990s, skin stayed rock-hard, felt like crap." These anecdotes are all subject to survivorship bias — users who saw no effect are less likely to post 30-year follow-ups.

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: Diffuse, not concentrated. Shaklee and Herbalife sell B-complex products containing PABA, but PABA is not a flagship single-ingredient MLM product.
• Influencer concentration: Bryan Johnson's gray-hair-reversal content (500K+ views) drives renewed interest, though he personally uses topical GR7/Mayraki, NOT oral PABA. Creates a misattribution halo where viewers assume PABA is part of his protocol when it isn't.
• Gerovital tourism marketing: Romania-based sellers (gerovital-pharmacy.com, drvclinic.co.uk) show clear commercial patterns — celebrity-endorsement lists (De Gaulle, Kennedy, Dietrich) are a classic social-proof fallacy. Testimonials heavily discounted.
• Sieve 1941 / Zarafonetis 1964 folklore: Cited verbatim across blogs and forums as if contemporary evidence. Classic folk-memory persistence of weak pre-RCT data.
• Astroturfing signals: Multi-ingredient "Anti-Gray Hair" Amazon blends (PABA + catalase + copper + saw palmetto) have repetitive affiliate-adjacent reviews. Standalone PABA reviews appear genuine.
• Commercial bias: LOW for standalone PABA (cheap, generic). HIGH for combo anti-gray products.
• DILI awareness gap: Folk community is largely unaware of the autoimmune-hepatitis case report (ACG 2020) from a PABA-containing hair supplement. Hepatologists now list PABA supplements in DILI reviews, but the biohacker community does not.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: GI intolerance at high doses (matches Clegg 1994's 18/73 KPAB withdrawals), universal relapse of any hair color effect on discontinuation, the paradox that established gray rarely reverses, and the practical impossibility of maintaining 12g/day (24 tablets) long-term.

Community experience diverges significantly from clinical data on: (a) the probability of hair repigmentation at 500mg — users expect it to work, but the best historical data used 200mg with 6-35% response in uncontrolled settings and no modern RCT exists; (b) the "oral sunscreen" framing in Japanese communities — no controlled human data support it and paradoxical photosensitization has been reported; (c) the low salience of hepatotoxicity risk — the autoimmune-hepatitis case from an OTC hair supplement is not on most users' radar; (d) the Bryan Johnson halo — drives purchases based on a protocol he is NOT actually using orally.

The most realistic community assessment comes from Longecity and peyroniesforum.net, where users note the evidence is historical, effects are modest or null, and the pill burden at therapeutic doses is a real compliance barrier.

Deep Dive: Mechanisms & Research

Mechanisms WITH Clinical Translation

Anti-fibrotic (Potaba): Zarafonetis proposed that PABA increases tissue oxygen consumption, leading to increased MAO activity and enhanced serotonin degradation. Since serotonin promotes fibroblast proliferation, reducing serotonin levels may slow fibrosis. This mechanism is plausible and consistent with the Peyronie's RCT results (plaque stabilization), but the clinical translation is marginal — curvature and function did not improve.

Interferon induction (Aktipol): Russian research (Akberova group, 1990s-2000s) demonstrated PABA induces endogenous interferon production, providing antiviral activity. Clinical translation exists in Russia (Aktipol ophthalmic drops for herpetic keratitis, 89.8% cure rate) but has never been replicated by Western labs. The interferon-inducing dose is very low (0.007% topical).

Preclinical Findings Worth Noting

Antioxidant activity: Akberova 1998 (PMID 9785016) demonstrated PABA antioxidant properties in vitro. Galbinur 2009 (PMID 20028256) showed PABA delayed retinal degeneration in rd10 mouse model of retinitis pigmentosa, attributed to antioxidant mechanism. Single study, no follow-up.

Retinal regeneration (zebrafish, 2024): He et al. (PMID 38103253, Neural Regen Res) showed PABA promotes retinal regeneration via Ascl1a activation in zebrafish. Single study; no mammalian or human translation in 2025-2026. Interesting mechanistically but very early.

Gut microbiome folate synthesis and ANTI-folate signaling: PABA is a substrate for bacterial dihydropteroate synthase (DHPS); gut bacteria use PABA to synthesize folate that can enter host folate pools. But a 2026 review by London RE (PMID 41527254, FEBS Lett) reframes this pathway — microbial biotransformation of PABA can also produce endogenous antifolates that modulate host folate status. This is theoretical: oral PABA supplementation could increase OR decrease net host folate depending on microbiome composition. Never measured in humans. A 2025 mosquito-host study (PMID 41409545, Front Cell Infect Microbiol) showed dietary PABA alters host-pathogen dynamics via the folate axis in Anopheles-Plasmodium — mechanistically interesting, not directly translatable.

Bacterial infection imaging (the most active 2024-2026 frontier): Because bacteria synthesize folate de novo from PABA but mammalian cells do not, radiolabeled PABA is a specific bacterial infection tracer. 11C-PABA PET/CT (PMID 40153540, 2025 AJRCCM, Johns Hopkins) visualized Mycobacteroides abscessus pulmonary infection. 18F-PABA PET detects infective endocarditis (PMID 39514763, 2025) and prosthetic joint infection (PMID 39432749, 2024). NCT05611905 (Johns Hopkins, N=13) completed first-in-human biodistribution of 11C-PABA with probenecid co-administration on 2025-11-08. This is diagnostic imaging — NOT a supplement use.

Dietary-adherence biomarker: PABA urinary recovery is the validated gold-standard marker of 24-hour urine collection completeness. PMID 41491972 (2026, Br J Nutr) confirmed PABA recovery does not bias salt-intake estimates in the UK cohort. Also PMID 41808949 uses NBT-PABA as a pancreatic exocrine function test. These are biomarker applications, not therapeutic.

PABA analogs (NOT PABA itself): A 2023 review (PMID 37893060) covers anticancer, anti-Alzheimer's, antibacterial, antiviral, antioxidant, and anti-inflammatory properties of PABA-derived compounds. These are synthetic analogs (e.g., HDAC-inhibitor PABA-GABA conjugates, PMID 41271065 2025), not the supplement form.

The Gerovital H3 Connection

Procaine (Novocaine) hydrolyzes in vivo into PABA + DMAE (dimethylaminoethanol). Romanian gerontologist Ana Aslan developed Gerovital H3 (injectable procaine) in the 1950s, claiming anti-aging benefits including hair repigmentation, improved vitality, and mood enhancement. The Gerovital literature is extensive but controversial — some double-blind trials showed modest benefits for mood and cognitive function in elderly patients (PMID 8349289). The longevity community sometimes combines oral PABA + DMAE as a "poor man's GH3," though in vivo procaine hydrolysis produces different kinetics than taking metabolites separately.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

No therapeutic trials for any PABA supplement indication (Peyronie's, scleroderma, hair, photoprotection) are registered on ClinicalTrials.gov as of April 2026. Apparent matches from keyword searches are false positives — "PABA" is used as an abbreviation for placebo or sham-drug codes in many trial descriptions. The pivotal Weidner 2005 (Peyronie's) and Clegg 1994 (scleroderma) RCTs both predate mandatory trial registration. No trials in East Asian registries (JPRN, CRiS, ChiCTR, Taiwan CTR).

Regulatory Status (from BioMCP)

• FDA: Potaba NDA 007663 originally approved 1959. WITHDRAWN 9 March 2022 (Federal Register Vol. 87, No. 46, 2022-04971). Reason: "Not shown to be effective for use under the conditions prescribed" — a DESI (Drug Efficacy Study Implementation) withdrawal covering all labeled uses (Peyronie's, scleroderma, dermatomyositis, morphea, linear scleroderma, pemphigus; already-rejected in 1970: rheumatoid arthritis, sarcoidosis, pulmonary fibrosis). Original sponsor Glenwood LLC was succeeded by Cheplapharm Arzneimittel GmbH, which withdrew its hearing request on 2020-07-02. Interstate shipment of unapproved potassium aminobenzoate is now unlawful. No re-approval activity detected. PABA remains available as a dietary supplement (not FDA-regulated as a drug; supplement doses ≤500mg are far below the 12g/day therapeutic dose).
• EMA: No central authorization (never submitted). Historically marketed in Germany (Potaba) through Cheplapharm; most EU member states no longer have current authorization. Available as unlicensed import or named-patient product in some jurisdictions.
• UK: Status ambiguous post-Cheplapharm succession.
• Romania / EU: No current authorization; available only as unlicensed import.
• Russia: Marketed as Aktipol (0.007% PABA ophthalmic solution) for herpetic keratitis. Approved as interferon inducer.
• WADA: Not listed as prohibited substance.
• Sunscreen use: Phased out in US/EU since the 1990s (photocontact dermatitis, cross-reactivity). US FDA removed PABA from the proposed sunscreen monograph's GRASE list in the 2019 rulemaking. Replaced by padimate O and modern filters (PMID 38777185, PMID 39640469).
• Regulatory context: Potaba was an orphan-like product — approved in 1959 under old standards, commercially marginal, manufacturer never invested in modern efficacy trials. The 2022 withdrawal codifies what Clegg 1994 and modern guideline bodies (AUA, EAU, Cochrane) already concluded: the efficacy evidence doesn't meet modern standards. PABA has no patent protection and no commercial sponsor willing to fund trials — a "commercial orphan" pattern that explains the lack of modern RCT data more than any pharma suppression.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale for each classification below.

Hype Check (Mode 1: Fallacy Radar)

• Appeal to tradition: "Used since the 1940s" — longevity of use ≠ evidence of efficacy. PABA was also used to treat typhus in the 1940s; we don't do that anymore either.
• Cherry-picking: Sieve 1941 (82% success) is universally cited; the later controlled study showing only 6% definite color change is rarely mentioned. Clegg 1994 (NULL scleroderma RCT) is almost never cited in supplement marketing.
• Single-researcher dependency: Nearly the entire historical therapeutic evidence base comes from C.J. Zarafonetis (Michigan, 1940s-1980s). When a second, modern, controlled RCT was finally attempted (Clegg 1994 scleroderma), it was NULL — which is what you'd expect when the original observational claims were inflated.
• "Vitamin B10" misnomer: PABA is not a vitamin for humans. We cannot use it to synthesize folate. Calling it a vitamin implies essential nutrient status it does not have.
• Hasty generalization: Animal antioxidant data (rat retinas, mouse degeneration, zebrafish regeneration) extrapolated to human supplement benefit without any human confirmation.
• Misattribution halo (2025-2026): Bryan Johnson's gray-hair content (500K+ views) drives PABA interest — but he uses topical GR7/Mayraki, NOT oral PABA. Purchases triggered by his content rest on a misreading of his protocol.

Evidence Gaps

• No RCT for hair repigmentation — the #1 reason people buy PABA has zero controlled evidence in 85 years
• No dose-finding studies at supplement doses (100-500mg) for any indication
• No pharmacokinetic studies at supplement doses in humans
• A modern scleroderma RCT DID exist — and was NULL (Clegg 1994). Filling the gap in the anti-fibrotic claim with a negative result.
• No head-to-head RCT vs collagenase, vitamin E, tamoxifen, pentoxifylline, or verapamil for Peyronie's
• No human antioxidant studies — only animal/in vitro
• No data on long-term safety at supplement doses (500mg/day for years)
• No human gut microbiome studies measuring whether oral PABA increases microbial folate production — the 2026 review (London) raised this as an open question
• No fertility, cardiovascular, bone, mood, sleep, muscle, cognition, or longevity data — all searched, nothing found
• No sex-stratified outcome data even where both sexes are potentially relevant

Bias Flags (Mode 4: First Principles)

• Zarafonetis single-lab problem (confirmed by Clegg 1994): One researcher's career worth of observational data did not survive the one modern controlled test that was ever attempted. Clegg 1994 is the "what would you have predicted?" result — and it's NULL.
• The procaine connection inflates perceived value: Association with Gerovital H3 and "Romanian anti-aging medicine" gives PABA borrowed prestige. But Gerovital's own evidence is mixed, and oral PABA ≠ injected procaine.
• "Not a vitamin" matters: Framing PABA as "Vitamin B10" implies a deficiency state exists and supplementation corrects it. Neither is true. There is no PABA deficiency syndrome because humans don't need PABA directly.
• Surviving mechanism is narrow: Anti-fibrotic (MAO → serotonin) is plausible but only tested at 12g/day and even at that dose, only half the story worked (plaque stabilization without curvature change; null scleroderma endpoints). No evidence the 500mg supplement dose has any measurable anti-fibrotic effect.
• Real DILI tail risk (underweighted by folk community): The immune-mediated hepatotoxicity pattern (Plüss 2022 RUCAM-confirmed with HLA-DR kinetics; ACG 2020 autoimmune hepatitis case from an OTC hair supplement) means the risk is unpredictable even at lower doses. Not catastrophic, but not zero — and the biohacker community is unaware of it.
• Cui bono (both directions): Nobody profits significantly from PABA promotion (cheap, no patents, no premium brands). But also nobody profits from studying it (no ROI on clinical trials). The 2022 FDA withdrawal was regulatory housekeeping, not new safety data. This "commercial orphan" status explains both the lack of modern evidence AND the lack of active suppression.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Minimal for standalone PABA (low-margin commodity). Significant for combo "anti-gray hair" products that bundle PABA with catalase, copper, saw palmetto — these make stronger claims than standalone PABA evidence supports.
• Influencer economics: Bryan Johnson's content is the 2025-2026 driver of renewed interest, but the attribution to PABA is wrong (he uses topical). Creates a halo that doesn't match the underlying evidence.
• Gerovital tourism marketing: Romania-based sellers (gerovital-pharmacy.com, drvclinic.co.uk) show clear commercial patterns with celebrity-endorsement lists and affiliate architectures. Testimonials heavily discounted.
• Counter-narrative manipulation: None detected. No pharma company has an incentive to attack PABA — it doesn't compete with any blockbuster drug. The 2022 FDA withdrawal is DESI regulatory housekeeping, not fearmongering.
• Cui bono summary: Nobody wins big if you take it. Nobody wins big if you don't. Low manipulation risk in both directions — except the Bryan-Johnson-halo and Gerovital-tourism pockets.
• Red team highlight (most concerning angle): The combination of (a) an 85-year-old unreplicated 1941 observation (Sieve) still driving 2026 purchasing decisions, and (b) an influencer halo (Bryan Johnson) driving renewed interest based on a protocol he isn't actually using orally. The legacy hype and the new hype converge on the same outcome: people buying PABA based on evidence they haven't actually examined.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 2/10 — No controlled evidence for any indication at supplement doses. Even at prescription doses (12g/day), the two modern controlled trials produced marginal (Peyronie's plaque stabilization only) or NULL (scleroderma) results. Guideline bodies (AUA 2015, EAU 2025, Cochrane 2023) actively recommend AGAINST oral PABA for the only indication where it had any RCT signal. Hair repigmentation claims rest on 1941 observational data. The 2024-2026 literature adds NO new efficacy data; the new science is imaging (diagnostic, not therapeutic) and microbiome antifolate theory.
• Opportunity cost: Minimal financial ($5-10/month) and complexity (1 pill). The marginal financial cost is trivial. The marginal compliance cost — adding yet another bottle — is non-trivial for anyone already running a complex stack. At 12g/day the opportunity cost is substantial (24 tablets/day, heavy GI burden, LFT monitoring, DILI tail risk).
• Hell Yes or No (Sivers test): No. The evidence does not produce an enthusiastic yes for any indication at any dose.
• Regret minimization: In 5 years you would NOT regret skipping supplement-dose PABA. You might regret high-dose Potaba for Peyronie's IF you developed the condition AND tolerated 12g/day AND accepted only plaque stabilization as an endpoint — but by that point, collagenase, traction devices, and intralesional agents are better-supported alternatives.
• Verdict: CONDITIONAL — defensible only in a narrow set of circumstances: (a) diagnosed Peyronie's with active plaque progression, no curvature-improvement expectation, and willingness to tolerate the 12g/day burden (and even then, guidelines recommend against); (b) low-dose gray-hair experimentation (≤500mg/day with LFT monitoring and photographic tracking) as cheap, low-risk, low-expected-benefit curiosity; (c) already taking a B-complex where PABA is a small component. For most users, including those interested in longevity, anti-aging, photoprotection, or scleroderma: SKIP.

Bottom Line

PABA is a historically fascinating compound that peaked in the 1940s-50s and never made it into the evidence-based era. The two modern controlled trials that exist — Weidner 2005 (Peyronie's) and Clegg 1994 (scleroderma) — produced marginal and NULL results respectively. Every major guideline body (AUA 2015, EAU 2025, Cochrane 2023, French AFU 2021) and every modern meta-analysis (Lee 2024, Pyrgidis 2022) recommends AGAINST oral PABA for its one indication with any RCT signal. The FDA walked away in 2022. At supplement doses (500mg), you are in a complete evidence desert — no RCT, no dose-finding, no PK data. The 2024-2026 literature adds genuine scientific novelty (11C-PABA PET imaging for bacterial infections, microbiome-generated antifolate theory) but NOTHING new for supplement indications. The compound is cheap, the commercial manipulation is low, and the safety profile at 500mg is likely fine for most people — but there is also no credible reason to take it. CONDITIONAL with a narrow set of valid conditions; SKIP for everyone else.

Practical Notes

Brands: NOW Foods PABA 500mg ($8/100 caps), Source Naturals 100mg ($7/250 tabs), NaturesPlus Sustained-Release 1000mg (~$20/60 tabs), Supersmart 500mg. All are commodity — no meaningful quality differentiation.

Storage: Room temperature, dry. No special requirements. Stable compound.

Cost: Among the cheapest supplements available. $5-15 per month at any dose level. Cost is never a barrier.

Absorption: Well-absorbed orally. Take with food to minimize GI upset. No known absorption interactions with common supplements.

If you insist on trying for gray hair:

• Start at 500mg/day with food for 1 month, assess GI tolerance
• If tolerated, consider 1,000mg/day (divided AM/PM) for 3-6 months
• Stack with B5 (pantothenic acid) per historical protocol (200mg PABA + 100mg calcium pantothenate)
• Take before/after photos at consistent lighting monthly
• Monitor: LFTs at baseline and 3 months if >1g/day
• Set a hard stop at 6 months — if no visible change, the evidence says it won't come
• DO NOT exceed 3g/day without medical supervision
• Effect (if any) will reverse on discontinuation

Sulfonamide warning: If you are prescribed any sulfa antibiotic (Bactrim/TMP-SMX, sulfasalazine, dapsone), STOP PABA immediately. This is a pharmacological absolute — PABA directly antagonizes the antibiotic mechanism.

What We Don't Know

• Whether PABA at 500mg has ANY measurable biological effect in humans (no PK/PD data at this dose)
• Whether oral PABA increases gut microbial folate production (plausible mechanism, never tested)
• The actual response rate for hair repigmentation with modern controls and measurement
• Whether the anti-fibrotic mechanism operates at doses below 12g/day
• Long-term safety at supplement doses over years
• Whether PABA has any synergy or antagonism with NMN, Shilajit, or other compounds in the current stack
• Whether the Japanese thyroid carcinogenesis signal (rat, chemical initiator model) has any human relevance
• Whether the Russian interferon-induction findings replicate in Western labs
• Whether combining PABA + DMAE actually recapitulates Gerovital H3 effects
• Why Sieve 1941 was never replicated — was it a methodological artifact, B-vitamin deficiency correction, or a genuine effect lost to history?

References

Systematic Reviews & Meta-Analyses

• Rosenberg JE, et al. (2023) Cochrane review — non-surgical therapies for Peyronie's disease. 14 RCTs, 1,810 men. PABA not among endorsed interventions. PMID: 37490423
• Lee JM, et al. (2024) Medical Treatment for Peyronie's Disease: Systematic Review and Network Bayesian Meta-Analysis. 24 RCTs, 1,643 patients. PABA NOT statistically significant; SUCRA ranked low. PMID: 37382281
• Pyrgidis N, et al. (2022) Assessment of conservative combination therapies for active and stable Peyronie's disease. PABA combinations not supported. PMID: 34924336
• Acer E, et al. (2020) Systematic review of premature graying treatment. PMID: 32654282
• PMC systematic review of medication-induced hair repigmentation. PMID: 32021854

Landmark Clinical Studies

• Weidner W, et al. (2005) Potaba vs placebo for Peyronie's disease — the pivotal RCT. N=103. Plaque stabilization but no curvature improvement. Eur Urol. PMID: 15774254
• Park NC, et al. (2016) Potaba monotherapy vs combination for Peyronie's. Korean study. N=109. PMID: 27169128
• Carson CC. (1997) Potaba for Peyronie's — retrospective, N=32. PMID: 9422444
• Zarafonetis CJ, Horrax TM. (1959) Potaba for Peyronie's — original case series. J Urol. PMID: 13655401
• Sieve BF. (1941) PABA and gray hair. Science, vol 94 — not indexed in PubMed
• Zarafonetis CJ. (1950) Darkening of gray hair during PABA therapy. J Invest Dermatol. PMID: 14794992

Anti-Fibrotic / Scleroderma

• Clegg DO, et al. (1994) Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. N=146, 48 weeks. NULL across all endpoints (skin mobility, thickening, oral aperture, hand ROM). Basis for FDA scleroderma efficacy rejection. J Rheumatol. PMID: 8151563
• Zarafonetis CJ. (1988) Retrospective, 467 scleroderma patients — 90% skin softening with KPAB (superseded by Clegg 1994 RCT). PMID: 3180546
• Zarafonetis CJ. (1959) Treatment of scleroderma with PABA. Ann Intern Med. PMID: 13627705
• Zarafonetis CJ. (1950) PABA in dermatomyositis and scleroderma — 6 cases. PMID: 15398860
• Silber MH, Gitlin N. (1973) Potaba for scleroderma — controlled trial. S Afr Med J. PMID: 4576830
• Gaby AR. (2006) Alternative therapies for scleroderma. PMID: 17217320

Safety

• Plüss M, et al. (2022) Potaba hepatotoxicity — RUCAM confirmed, HLA-DR kinetics. Front Pharmacol. PMID: 36059975
• DRESS syndrome from Potaba — first reported case. (2024) PMID: 39292842
• Roy MK, Carrier S. (2008) Potaba hepatotoxicity — compiled 6 cases. PMID: 18624965
• Al Attar A, et al. (2018) Acute liver injury from Potaba. PMID: 29928188
• Kantor GR, Ratz JL. (1985) Potaba hepatotoxicity — first report. JAAD. PMID: 3878370
• Zarafonetis CJ. (1986) LFT findings in Potaba-treated patients — safety review. PMID: 3487559
• Worobec SM. (1984) Dangers of orally administered PABA — hypoglycemia. JAMA. PMID: 6608591
• Hasumura M, et al. (2005) PABA promoted thyroid carcinogenesis in rats. (Japanese). PMID: 15843508
• Stoevesandt J, et al. (2010) Systemic photosensitization from oral PABA. PMID: 20153994

Mechanism Studies

• Akberova SI. (1999) PABA as interferon inducer. (Russian). PMID: 10483491
• Akberova SI. (1998) PABA as antioxidant. (Russian). PMID: 9785016
• Akberova SI. (2000) Aktipol for herpetic keratitis — N=118, 89.8% cure. PMID: 11055216
• Akberova SI. (1995) PABA + acyclovir synergy in herpes. (Russian). PMID: 8660116
• Galbinur T, et al. (2009) PABA slowed retinal degeneration in rd10 mice. (Israeli). PMID: 20028256
• PABA analogs review — anticancer, anti-Alzheimer's etc. (2023) PMID: 37893060

Regulatory

• FDA. (2022) Withdrawal of approval for Potaba NDA 007663. Federal Register Vol. 87, No. 46 (Document 2022-04971). 9 March 2022.
• Tienforti D, et al. (2024) Analysis of evidence on nutraceutical interventions for Peyronie's disease — guideline-based critical review. Sex Med Rev. PMID: 38807529
• Abdel Azim S, et al. (2025) Sunscreens part 2: Regulation and safety. J Am Acad Dermatol. PABA off-market confirmation. PMID: 38777185
• Topical sunscreens narrative review — PABA listed as historic contact sensitizer. (2024) Indian Dermatol Online J. PMID: 39640469

Guidelines

• Salonia A, et al. (2025) EAU Guidelines on Male Sexual and Reproductive Health: 2025 Update — Peyronie's. Strong recommendation AGAINST oral treatment for curvature correction. Eur Urol. PMID: 40340108
• AUA Peyronie's Disease Guideline. (2015) Nehra A et al. "Clinicians should not offer potassium para-aminobenzoate for the reduction of penile curvature." J Urol. PMID: 26066402
• French AFU (2021) Peyronie's disease guidelines — oral PABA not recommended. PMID: 33941460
• Trost LW, et al. (2007) Potaba review — only oral agent with positive RCT for plaque reduction, but limited effect. PMID: 17352513
• Hauck EW, et al. (2006) Critical analysis of conservative Peyronie's therapy. PMID: 16698449

Historical / Rickettsial

• Rose HM. (1945) PABA for Rocky Mountain spotted fever. JAMA. PMID: 21006160
• Zarafonetis CJ. (1946) PABA for experimental scrub typhus. PMID: 21024156
• Mackie BS. (1999) "The PABA Story" — oral sun protection advocacy. PMID: 10098293

Pharmacology

• Tisdale JE. (1995) PABA drug interaction study — 6g/day × 5 days. PMID: 8786250
• Upton AC, Zarafonetis CJ. (1950) Prolonged PABA in rats — no significant toxicity. PMID: 14808289
• London RE. (2026) Microbiome-generated antifolates — gut-microbial PABA biotransformation to endogenous antifolates, host-folate modulation theory. FEBS Lett. PMID: 41527254

2024-2026 New Literature (Bacterial Infection Imaging + Biomarker Applications)

• Masias-Leon et al. (2025) Dynamic 11C-PABA PET/CT for visualizing pulmonary Mycobacteroides abscessus infection. Johns Hopkins. Am J Respir Crit Care Med. PMID: 40153540
• Schulte et al. (2025) 2-[18F]F-PABA PET specifically detects infective endocarditis. J Infect Dis. PMID: 39514763
• Pollard-Kerning et al. (2024) 18F-PABA nitro-prodrug PET for prosthetic joint infection. ACS Infect Dis. PMID: 39432749
• Jones KS, et al. (2026) Self-report of 24-h urine completeness compared with PABA recovery does not bias salt-intake estimates. Br J Nutr. PMID: 41491972
• He M, et al. (2024) P-aminobenzoic acid promotes retinal regeneration through activation of Ascl1a in zebrafish. Neural Regen Res. PMID: 38103253
• Costa et al. (2025) Dietary para-aminobenzoic acid modulates Anopheles/Plasmodium susceptibility via folate-axis. Front Cell Infect Microbiol. PMID: 41409545
• ACG 2020 case report (S2594). Autoimmune hepatitis due to PABA-containing hair supplement — 37F. Am J Gastroenterol.